SPIA
ELEV

Steward Partners Investment Advisory’s Elevation Oncology ELEV Stock Holding History

Steward Partners Investment Advisory’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-500
Closed -$475 – 3338
2022
Q4 		$475 Hold
500
– – ﹤0.01% 3201
2022
Q3 		$1K Hold
500
– – ﹤0.01% 3114
2022
Q2 		$1K Hold
500
– – ﹤0.01% 3105
2022
Q1 		$1K Hold
500
– – ﹤0.01% 3175
2021
Q4 		$3K Hold
500
– – ﹤0.01% 2938
2021
Q3 		$4K Hold
500
– – ﹤0.01% 2853
2021
Q2 		$7K Buy
+500
New +$6.18K ﹤0.01% 6371

Other funds holding ELEV

ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Steward Partners Investment Advisory's ELEV Position: Q1 2023 in Review

Steward Partners Investment Advisory sold out of Elevation Oncology (ELEV) in Q1 2023, closing a stake of 500 shares — an estimated $475 sold.

Steward Partners Investment Advisory first reported a position in ELEV in Q2 2021 and held it in 7 quarters. The position peaked at $7K in Q2 2021. 27 funds tracked by Wall St. Rank hold ELEV as of Q1 2023.

  • Steward Partners Investment Advisory reported no remaining Elevation Oncology position as of Q1 2023 after selling out during the quarter.
  • Steward Partners Investment Advisory sold 500 Elevation Oncology shares in Q1 2023, an estimated $475.
  • Steward Partners Investment Advisory first reported a position in Elevation Oncology in Q2 2021 and held it in 7 quarters.
  • Steward Partners Investment Advisory's Elevation Oncology position peaked at $7K in Q2 2021.
  • 27 funds tracked by Wall St. Rank held Elevation Oncology as of Q1 2023.

Based on Steward Partners Investment Advisory's 13F filing for Q1 2023, filed 15 May 2023.